Gossamer Bio Restructures Debt, Secures Full Control of Lead Drug Candidate - Gossamer Bio (NASDAQ:GOSS)

Gossamer Bio plans a September 2026 NDA filing for seralutinib following FDA feedback and reacquires global rights.

Raccontata dabenzinga.com